The American Journal of Medicine
Volume 122, Issue 6, Supplement , Pages S11-S24, June 2009

Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus

  • Matthew P. Gilbert, DO, MPH
    • ,
  • Richard E. Pratley, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Richard E. Pratley, MD, Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Given C33189, Beaumont Avenue, Burlington, Vermont 05405

Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont, USA

Abstract 

This article aims to provide an overview of efficacy and safety data on glucagon-like peptide–1 (GLP-1) receptor agonists and dipeptidyl peptidase–4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.

Keywords: DPP-4, exenatide-LAR, GLP-1 receptor agonist, liraglutide, sitagliptin

 

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00277-0

doi:10.1016/j.amjmed.2009.03.013

The American Journal of Medicine
Volume 122, Issue 6, Supplement , Pages S11-S24, June 2009

Article Tools

* Image Usage & Resolution